An in-depth thought leadership whitepaper explaining how sponsors can operationalize the FDA’s 2025 guidance on inclusive and representative clinical trial design. It outlines current industry ...
In a recent video interview with Applied Clinical Trials, Marc Buyse, ScD, founder and CEO of IDDI, discussed how growing trial complexity is creating new challenges for data conf ...
This article explores how adopting a “workflow” mindset anchored in measurable sponsor outcomes meets this challenge, ultimately yielding the lower costs, higher quality, and an architecture ready for ...
In addition to improving payment speed, accuracy, and transparency, modern payment technology is creating new opportunities to further improve the trial experience. For example, AI is being used to ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian ...
At the SCOPE Summit, Tekton Research shares how its physician-led clinical trial network is helping accelerate research in neuroscience and cardiometabolic disease. By pairing pra ...
In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, reflects on the gap between sponsor expectations and statistical reality, drawing on lessons from the COVID era to argue for more ...
Closing the gender gap in data science and tech requires tackling barriers at every stage, from early education through career advancement, while actively challenging the unconscious biases that ...
In today’s ACT Brief, we highlight how Bayesian methods are reshaping adaptive trial design, a major eSource partnership is ...
The Patient Advocate Foundation and the PAN Foundation have announced a strategic merger to create the nation’s most ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
ACT Brief: Trial Data Transparency, Protocol Design Drives Enrollment, FDA Shifts Approval Standards
In today's ACT Brief, we examine why transparency in complex trial designs is essential for data confidence, how protocol structure—not operational effort—determines recruitment success, and the FDA's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results